Eilean Therapeutics is a small molecule oncology drug discovery company committed to defeating and curing cancer. Many malignant tumors develop resistance to treatment either by developing mutations or escape mechanisms, thereby limiting the activity of current therapeutics.  

At Eilean, we develop differentiated small molecules that target fundamental biological pathways with resistant mutations and escape mechanisms in hematologic malignancies.  By developing pan-variant therapies that target the major drivers of cancer resistance, we overcome the limitations of current oncology therapeutics and develop first in class and best in class therapeutics for hematologic malignancies.

Eilean is a privately held biotechnology company established in 2022.